

OCT 6 1998

K983109

510(k) Summary of Safety and Effectiveness

Device Name	Model 545GE-64 Phased Array Musculoskeletal Flex Coil Package consisting of Model 543GE-64 Phased Array Upper Extremity Flex Coil and Model 544GE-64 Phased Array Lower Extremity Flex Coil
Applicability	Compatible with GE Signa 1.5T MRI systems with Phased Array option
Reason for 510(k)	New device
Classification Name	Magnetic Resonance Diagnostic Device
Device Classification Panel	Radiology
Device Classification Number	892.1000
Product Code	90LNH
Common Name	Magnetic Resonance Imaging Coil
Proprietary Name	Model 545GE-64 Phased Array Musculoskeletal Flex Coil Package consisting of Model 543GE-64 Phased Array Upper Extremity Flex Coil and Model 544GE-64 Phased Array Lower Extremity Flex Coil
Establishment Registration Number	2183683
Address of MFG Facility	Medical Advances, Inc. 10437 Innovation Drive Milwaukee, WI 53226
Point of Contact	Thomas E. Tynes Vice President - Operations (414) 258-3808 Ext. 407
Classification	Class II
Intended Uses	
Diagnostic Uses	2D, 3D imaging, proton density, T1 and T2 weighted imaging. 2D, 3D time of flight, phase contrast imaging.

Anatomic Regions

Bones, soft tissue, musculoskeletal structures and vascular structures in the upper and lower extremities

Standards

Performance Standards

None Established under Section 514

Voluntary Safety Standards

UL 544	Medical and Dental Equipment
UL 94	Tests for Flammability of Plastic Materials
IEC 601-1	General Safety Requirements for Medical Electrical Equipment
CPAI-84	Specification for Flame Resistant Material Used in Camping Tentage

Overview

The Radiology Devices Panel considered potential concerns regarding the safe and effective operation of Magnetic Resonance Diagnostic Devices when they recommended reclassification to Class II on July 27, 1987. After reclassification, the FDA's Center for Devices and Radiological Health released a draft guidance document for the content and review of Magnetic Resonance Diagnostic Device premarket notification submissions that offered clarification of these concerns. The following is a summary of the information contained within this premarket notification that addresses these concerns:

The GE 1.5T Signa MRI system operated with the Medical Advances Phased Array Musculoskeletal Flex Coil Package is substantially equivalent to the same system operated with the legally marketed predicate devices listed in section 4.0, within the Class II definition of Magnetic Resonance Diagnostic Device with respect to the safety parameter action levels:

Safety Parameters

Maximum Static Magnetic Field:	No change
Rate of Magnetic Field Strength Change:	No change
RF Power Deposition:	No change
Acoustic Noise Levels:	No change

Imaging Performance Parameters

Specification Volume:	No change
Signal-to-Noise Ratio:	No change
Image Uniformity:	No change
Geometric Distortion:	No change
Slice Thickness and Gap:	No change
High Contrast Spatial Resolution:	No change

General Safety and Effectiveness Concerns

The device contains instructions for use. It includes indications for use, precautions, cautions, contraindications, warnings and quality assurance testing. This information assures safe and effective use of the device.

Substantial Equivalence Summary

The GE 1.5T Signa MRI system operated with the Medical Advances Phased Array Musculoskeletal Flex Coil Package addressed in this PMN, has the same intended use and technological characteristics as the same system operated with the identified legally marketed predicate devices. The use of these coils does not affect the GE Signa system safety parameter specifications.



OCT 6 1998

Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850Thomas E. Tynes
Vice President-Operations
Medical Advances, Inc,
10437 Innovation Drive
Milwaukee, WI 53226Re: K983109
Model 545GE-64 Phased Array Musculoskeletal Flex Coil
Package consisting of Model 543GE-64
Dated: September 3, 1998
Received: September 4, 1998
Regulatory class: II
21 CFR 892.1000/Procode: 90 MOS

Dear Mr. Tynes:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4613. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address "<http://www.fda.gov/cdrh/dsma/dsmamain.html>".

Sincerely yours,

Lillian Yin, Ph.D.
Director, Division of Reproductive,
Abdominal, Ear, Nose and Throat
and Radiological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

510(k) Number (if known): K98 3109

Device Name: Model 545 Series: Phased Array Musculoskeletal Flex Coil Package consisting of 543 Series Phased Array Upper Extremity Flex Coil and 544 Series Phased Array Lower Extremity Coil

Indications for Use:

Magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) of the bones, soft tissue, musculoskeletal structures and vascular structures of the upper and lower extremities.

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

David A. Seymour
(Division Sign-Off)
Division of Reproductive, Abdominal, ENT,
and Radiological Devices
510(k) Number K983109

Prescription Use X
(Per 21 CFR 801.109)

OR

Over-The-Counter Use _____

(Optional Format 1-2-96)